University at Buffalo - The State University of New York
Skip to Content
Matthew                        Barth

Matthew J. Barth MD

Department of Pediatrics

Assistant Professor

Specialty/Research Focus

Pediatric Hematology-Oncology; Pediatrics

 
Professional Summary:

I am a pediatric hematologist/oncologist. I see patients in UBMD pediatric outpatient clinics, and I care for young patients who are admitted to Roswell Park Cancer Institute (RPCI).

In addition to my clinical practice, I have a keen interest in hematological malignancies and the use of targeted therapies in their treatment. As a fellow in the lymphoma translational research laboratory at RPCI, I began investigating novel therapeutic anti-CD20 antibodies in cell-line and xenograft models of rituximab resistant B-cell non-Hodgkin lymphoma (B-NHL). Based on my initial findings with the antibody ofatumumab, the University at Buffalo granted me the Dr. Henry C. and Bertha H. Buswell Fellowship, an award for promising physician-scientists who are in the beginning stages of their careers. The award allowed me to continue my work with this novel monoclonal antibody and begin exploring why B-cell lymphoma cells become resistant to multiple therapeutic modalities, including anti-CD20 immunotherapy and traditional cytotoxic chemotherapy. For children with relapsed/refractory disease, this resistance portends a survival rate that is less than 20 percent.

Using cell-line models of resistant disease and a variety of techniques such as gene expression profiling, phosphoproteomics, phospho-flow cytometry and western blotting, I have sought to characterize aberrant signal transduction pathway activation in the setting of resistant B-NHL and the ability to target relevant pathways as a means to overcome or bypass therapeutic resistance. These efforts have led to collaborative research with several investigators throughout the country who have similar interests, e.g., the clinical investigation of the anti-CD20 monoclonal antibody rituximab in childhood B-NHL.

In addition to my basic science and translational research, I am involved in developing trials that investigate other novel therapies in the setting of relapsed/refractory disease. I am co-PI of an investigator-initiated trial studying the anti-CD20 monoclonal antibody obinutuzumab, in combination with chemotherapy, for relapsed/refractory childhood B-NHL. I am also an industry-sponsored investigator researching the role of rituximab in the treatment of de novo childhood mature B-NHL. Additionally, I serve on the study committees of ongoing clinical trials through the Children’s Oncology Group.

I often supervise residents on their research projects and periodically welcome medical students, college students and high school students to work with me in the lab—mostly as part of the RPCI summer research program.

I teach medical students, residents and fellows rotating through pediatric hematology and oncology, in outpatient clinics and at the bedside on inpatient units. Using brief impromptu lectures/discussions, I also teach these trainees about disease processes they encounter as they rotate through hematology/oncology. I also lecture the pediatric residents during the hematology/oncology portion of their didactic series. Additionally, I teach our hematology/oncology fellows, in small-group didactic lectures and in both inpatient and outpatient clinical encounters.

Education and Training:
  • Fellowship, Pediatric Hematology/Oncology, University at Buffalo (2011)
  • Residency, Pediatrics, University at Buffalo (2008)
  • Internship, Pediatrics, University at Buffalo (2006)
  • MD, Medicine, SUNY Upstate Medical University (2005)
  • BA, Chemistry, Stonehill College, cum laude (1999)
  • BS, Biology, Stonehill College, cum laude (1999)
Employment:
  • Assistant Professor, Pediatrics, University at Buffalo (2014-present)
  • Attending Physician, Division of Hematology/Oncology, UBMD Pediatrics, Women and Children‘s Hospital of Buffalo (2011-present)
  • Research Assistant Professor, Pediatrics, University at Buffalo (2011–2014)
  • Research Assistant, Upstate Medical University, College of Medicine (2002)
  • Technical Research Assistant, Pulmonology, Channing Laboratory, Brigham and Women‘s Hospital (1999–2001)
  • Research Associate, Stonehill College (1998)
  • Research Assistant, Stonehill College (1997–1998)
Awards and Honors:
  • International Society of Paediatric Oncology: Young Investigator Award (2016)
  • 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma: Outstanding Translational Biology Research (2015)
  • National Institutes of Health: Loan Repayment Program Award (2012)
  • 11th International Conference on Malignant Lymphoma: Travel Award (2011)
  • Roswell Park Cancer Institute: Best Basic Science Fellow Research Report (2011)
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Thomas F. Frawley, MD Residency Research Fellowship (2011)
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Henry C. and Bertha H. Buswell Fellowship (2011)

Research Expertise:
  • Hematological malignancies: Use of targeted therapies in their treatment
  • Pediatric lymphoma
Grants and Sponsored Research:
  • July 2013–June 2016
    Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL
    St. Baldricks Foundation
    Role: Principal Investigator
    $220,000
  • November 2014–October 2015
    Targeting CD30 Using Brentuximab Vedotin (SGN-35), an Anti-CD30 Antibody Drug Conjugate, in B-NHL
    Wildermuth Memorial Foundation
    Role: Principal Investigator
    $330,000
  • November 2013–October 2015
    Preclinical and Translational Investigation of Ibrutinib (PCI-32765) in Childhood, Adolescent and Young Adult B-Cell Non-Hodgkin Lymphoma
    Janssen Pharmaceuticals
    Role: Co-Investigator
  • September 2012–December 2014
    Targeted Therapeutic Approaches to Overcoming Resistance in Pediatric Aggressive B-NHL
    Hyundai Hope on Wheels
    Role: Principal Investigator
    $250,000
  • July 2011–June 2014
    Biological Activity of Lenalidomide and Ofatumumab in B-cell Lymphoma
    University at Buffalo: Henry C. and Bertha H. Buswell Research Fellowship
    Role: Principal Investigator
    $240,000
  • February 2012–December 2013
    Biological Activity of Histone Deacetylase Inhibitors in the Treatment of Pediatric Lymphoma
    Roswell Park Alliance Foundation
    Role: Principal Investigator
    $40,000

Journal Articles:
See all (7 more)
Abstracts:
  • Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood. 2012; 120(21).
  • Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL). Blood. 2012; 120(21).
  • Frys S, Barth MJ, Gu J, Mavis C, Gibbs JF, Czuczman MS, Hernandez-Ilizaliturri FJ. Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors. Blood. 2012; 120(21).
  • Czuczman NM, Barth MJ, Dawar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. Blood. 2012; 120(21).
  • Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri FJ, Czuczman MS. Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models. Blood. 2012; 120(21).
  • Dawar R, Barth MJ, Mavis C, Skitzki J, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models. J Clin Oncol. 2012; 30(Sup15).
  • Barth MJ, Pendurti G, Mavis C, Czuczman NM, Gibbs JF, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived from Patient Tumor Samples. Blood. 2011; 118(21).
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. Blood. 2010; 116(21).
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma. J Clin Oncol. 2010; 28(Sup15).

Professional Memberships:
  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Society of Pediatric Hematology/Oncology
  • Children‘s Oncology Group
Presentations:
  • "Clinical Application of Tumor Genomics in Pediatric Oncology" Pediatric Grand Rounds, Women and Children's Hospital of Buffalo (2017)
  • "Reduced Burden of Therapy in Intermediate Risk Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial" 48th Congress, International Society of Paediatric Oncology (2016)
  • "Childhood Cancer Awareness" AM Buffalo, WKBW (2016)
  • "Ways to Improve Treatment for Certain Types of Childhood Cancer" WNY Living, WGRZ (2016)
  • "MK-2206, an Akt Inhibitor, Decreases Proliferation, Induces Cell Cycle Arrest and Increases Responsiveness to Chemotherapy in Therapy-Sensitive and –Resistant Burkitt Lymphoma Cell Line Models" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Targeting the PI3K/Akt/Mtor Pathway Improves Chemoresponsiveness in Cell Line Models of Chemotherapy Sensitive and Resistant Burkitt Lymphoma" 47th Congress, International Society of Paediatric Oncology (2015)
  • "Deregulation of the PI3K/Akt Signal Transduction Pathway is Associated With the Development of Chemotherapy Resistance and Can Be Effectively Targeted To Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models" Annual Meeting, American Society of Hematology (2014)
  • "Exogenous Overexpression of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells to RTX Induced Apoptosis" Annual Meeting, American Society of Hematology (2013)
  • "Histone Deacetylase Inhibitors Enhance Cell Death in Burkitt Lymphoma Cells by Modulating Expression of the WNT/Beta-Catenin Pathway and Survivin" Annual Meeting, American Society of Hematology (2013)
  • "MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme (NAE), is Active in Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo" Annual Meeting, American Society of Hematology (2013)
  • "Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion of MIR17HG in Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity" Annual Meeting, American Society of Hematology (2013)
  • "Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors" Annual Meeting, American Society of Hematology (2012)
  • "Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma" Annual Meeting, American Society of Hematology (2012)
  • "MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL)" Annual Meeting, American Society of Hematology (2012)
  • "Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models" Annual Meeting, American Society of Hematology (2012)
  • "Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models" Annual Meeting, American Society of Hematology (2012)
  • "Obinutuzumab (GA101): Exhibits Enhanced Cell Death and ADCC Compared to Rituximab in RTX Resistant and Sensitive Cell Lines Against B-Cell Non-Hodgkins Lymphoma" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, New York Medical College, Westchester Medical Center and Maria Fareri Children’s Hospital (Valhalla, NY); Justus-Liebig University and Children’s University Hospital (Germany), and Pediatric Cancer Research Foundation (Irvine, CA) (2012)
  • "Outcome of Advanced Stage (III/IV) Intermediate-Risk Patients with Mature B-NHL Using Rituximab Plus FAB Group B4 Chemotherapy: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, New York Medical College, Westchester Medical Center and Maria Fareri Children’s Hospital (Valhalla, NY); Justus-Liebig University and Children’s University Hospital (Germany), and Pediatric Cancer Research Foundation (Irvine, CA) (2012)
  • "Safety and Pharmacokinetics of Rituximab in Combination with FAB Chemotherapy in Children and Adolescents with Stage III/IV Mature B-NHL and B-cell Leukemia +/- CNS Disease: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, New York Medical College, Westchester Medical Center and Maria Fareri Children’s Hospital (Valhalla, NY); Justus-Liebig University and Children’s University Hospital (Germany), and Pediatric Cancer Research Foundation (Irvine, CA) (2012)
  • "Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models" Annual Meeting, American Society of Clinical Oncology (2012)
  • "Activity of Rituximab (RIT) and Ofatumumab (OFA) Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines by Complement Dependent Cytotoxicity and Antibody Dependent Cell Mediated Cytotoxicity" Internal Medicine 2012, American College of Physicians Internal Medicine (2012)
  • "Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived from Patient Tumor Samples" Annual Meeting, American Society of Hematology (2011)
  • "Safety and Pharmacokinetics (PK) of Rituximab (R) in Combination with FAB Chemotherapy in Children and Adolescents (C+A) with Stage III/IV Mature B-NHL: A Children‘s Oncology Group Report" 11th International Conference on Malignant Lymphoma (ICML), European Society for Medical Oncology and Japanese Society of Medical Oncology (2011)
  • "Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines, Rituximab-Resistant Cell Lines, Lymphoma Xenografts" Annual Meeting, American Society of Hematology (2010)
  • "Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma" Annual Meeting, American Society of Clinical Oncology (2010)
  • "Central Venous Line Related Deep Venous Thrombosis in Pediatric Patients" Pediatric Grand Rounds, Women and Children's Hospital of Buffalo (2009)
  • "Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset COPD" International Conference, American Thoracic Society (2002)
  • "B2 Adrenergic Receptor Polymorphisms are Not Associated with Rate of Lung Function Decline in a Population-based Study of Men" International Conference, American Thoracic Society (2001)
  • "Family-based Association Analysis of ARG130GLN IL-13 Polymorphism in the Childhood Asthma Management Program" International Conference, American Thoracic Society (2001)
  • "Family-based Association Analysis of B2AR-16 Polymorphism in the Childhood Asthma Management Program" International Conference, American Thoracic Society (2001)
See all (20 more)
Service Activities:
  • Children‘s Oncology Group: Non-Hodgkin Lymphoma Committee; Committee Member (2011–present)
  • Children‘s Oncology Group: Study Committee; Committee Member (2011–present)
  • Children‘s Oncology Group: Young Investigator Mentoring Program (Mitchell Cairo, MD); Student Mentor (2011–present)
  • Journal of Leukemia and Lymphoma; Reviewer

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

UBMD Pediatrics
Division of Hematology/Oncology
219 Bryant Street
Buffalo, NY 14222
Phone: (716) 878-7349
Fax: (716) 888-3801
Email: mbarth@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile